Market cap
$52 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
4.3
P/B Ratio
1.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -- | -- | -- |
| Net Profit | -19.93 | -- | -90.74 | 22.40 | 12.81 |
| EPS | 22.58 | -- | -37.75 | 23.97 | 8.40 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-25 | Dec-24 | Dec-23 |
| EBIT-Margin
| -31.44 | -31.44 | -- | -31.44 | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| 49.68 | -176.23 | 33.08 | 13.39 | 102.55 |
| Return on Capital
| 91.13 | -29.05 | 41.75 | 17.25 | 214.39 |
| Return on Assets
| -142.95 | -145.05 | -145.40 | -134.09 | -149.37 |
| Debt to Equity (x)
| -- | -- | -0.08 | -0.27 | -0.18 |
Profitability
ROCE
41.75
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
41.75
|
17.25
|
214.39
|
-187.03
|
-231.59
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
33.08
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
33.08
|
13.39
|
102.55
|
-615.23
|
-414.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-145.40
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
-145.40
|
-134.09
|
-149.37
|
-108.86
|
-187.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
-31.44
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
-49.43
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-1.00
--
Year on year growth in net sales
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
-1.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
--
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
87.43
|
53.49
|
47.77
|
-122.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-90.74
--
Year on year growth in profit after tax
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
-90.74
|
81.57
|
52.71
|
45.95
|
-92.98
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
--
--
Year on year growth in earnings per share
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
0.82
|
0.63
|
-4.93
|
0.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.08
--
Total debt / Net worth
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
-0.08
|
-0.27
|
-0.18
|
-1.26
|
0.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.08
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
-0.08
|
-0.27
|
-0.10
|
-0.44
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.31
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
0.31
|
0.11
|
0.07
|
0.87
|
4.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
-1.75
|
-13.82
|
-17.54
|
-52.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
42.74
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
2.71
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
78.06
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
--
|
--
|
1,155.92
|
353.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
--
|
-0.02
|
-0.01
|
-0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
--
|
-0.01
|
-0.03
|
0.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
--
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
--
|
--
|
-0.21
|
0.17
|
0.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|